Exploring Hepatotoxicity and Treatment Outcomes of Targeting KRAS G12C Mutations in mNSCLC - Episode 6

Disease Progression Beyond Frontline KRAS G12C Inhibitors

,

Expert oncologists discuss patients who may progress to the second line setting with KRAS G12C mutations.